Loading clinical trials...
Loading clinical trials...
The purpose of this open-label, single arm, multi-center Expanded Treatment Protocol (ETP) was to provide early access to ruxolitinib and evaluate safety information in patients with polycythemia vera...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT07357727 · Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), and more
NCT06976918 · Primary Myelofibrosis, Secondary Myelofibrosis, and more
NCT06343805 · Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, and more
NCT05123365 · Myeloproliferative Neoplasm, MPN, and more
NCT06327100 · Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, and more
Novartis Investigative Site
Linz
Novartis Investigative Site
Salzburg
Novartis Investigative Site
Wels
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions